• 1
    Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N. Engl. J. Med. 1995; 332: 15291534.
  • 2
    Yonkers KA, Halbreich U, Freeman E et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997; 278: 983988.
  • 3
    Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet. Gynecol. 2002; 100: 12191229.
  • 4
    Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J. Affect. Disord. 2005; 85: 317321.
  • 5
    Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am. J. Psychiatry 2004; 161: 343351.
  • 6
    Steiner M, Hirschberg AL, Bergeron R, Holland F, Gee MD, Van Erp E. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. 2005; 193: 352360.
  • 7
    Hsiao MC, Liu CY, Chen KC, Hsieh TT. Characteristics of women seeking treatment for premenstrual syndrome in Taiwan. Acta Psychiatr. Scand. 2002; 106: 150155.
  • 8
    Hsiao MC, Liu CY, Chen KC, Hsieh TT. Characteristics of women using a mental health clinic in a gynecologic out-patient setting. Psychiatry Clin. Neurosci. 2002; 56: 459463.
  • 9
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Association, Washington, DC, 1994.
  • 10
    Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998; 59: 2233.
  • 11
    Reid RL, Yen SS. The premenstrual syndrome. Clin. Obstet. Gynecol. 1983; 26: 710718.
  • 12
    Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1967; 6: 278296.
    Direct Link:
  • 13
    Hamilton M. The assessment of anxiety scales by rating. Br. J. Med. Psychol. 1959; 32: 5055.
  • 14
    Raft D, Spencer RF, Toomey T, Brogan D. Validity of the Zung depression scale (SDS) in medical outpatients. Md State Med. J. 1979; 28: 3941.
  • 15
    Spielberger CD, Borsuch RL, Lushene RE. State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA, 1970.
  • 16
    Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 1996; 16: 38.
  • 17
    Cohen LS, Soares CN, Yonkers KA et al. Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial. Psychosom. Med. 2004; 66: 707713.
  • 18
    Landen M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007; 32: 153161.
  • 19
    Sundblad C, Wikander I, Andersch B, Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: Efficacy and side-effects during ten cycles of treatment. Eur. Neuropsychopharmacol. 1997; 7: 201206.
  • 20
    Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial. Clin. Ther. 2002; 24: 417433.
  • 21
    Hsiao MC, Liu CY. Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Psychiatry Clin. Neurosci. 2003; 57: 317321.
  • 22
    Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: The emerging gold standard? Drugs 2002; 62: 18691885.